Literature DB >> 10854086

Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?

N M Kaplan1.   

Abstract

In the past few years, angiotensin II-receptor blockers have become available and are being heavily marketed and increasingly used. In various ways they differ from angiotensin-converting enzyme inhibitors (ACEIs). Until outcome data are available, they should continue to be used primarily in patients who should receive an ACEI but cannot tolerate the drug because of cough.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854086     DOI: 10.1038/sj.jhh.1000992

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  4 in total

Review 1.  Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

Authors:  K A Payne; S Esmonde-White
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

2.  Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers.

Authors:  Iman O Sherif; Laila A Al-Mutabagani; Anwar M Alnakhli; Mohamed A Sobh; Hoda E Mohammed
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-29

3.  Royal Jelly and Aliskiren mutually annul their protective effects against gentamicin-induced nephrotoxicity in rats.

Authors:  Mohd Alaraj
Journal:  Vet World       Date:  2020-12-14

4.  Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.

Authors:  Joel M Neutel; David H G Smith; Michael A Weber; Antonia C Wang; Harvey N Masonson
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.